GlobeNewswire Inc | Nov 11, 2020 08:00AM EST

November 11, 2020

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body,announced today that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020.

Cue Biopharma will provide an overview highlighting the Immuno-STAT (Selective Targeting and Alteration of T cells) platform, its expanding pipeline and anticipated milestones. The presentations will also include an update on the Companys ongoing Phase 1 monotherapy dose escalation trial of CUE-101 including details pertaining to patients from cohorts 4, 5, and 6 being treated for HPV16-driven recurrent/metastatic head and neck cancer.

Additional conference details can be found below:

Stifel Virtual Healthcare Conference 2020Date and Time: November 18, 2020 at 9:20 a.m. ESTWebcast Link: https://wsw.com/webcast/stifel27/cue/1908496A live and archived webcast of the presentation will be available in theInvestors section of the Company?s website atwww.cuebiopharma.com. . Jefferies Virtual London Healthcare ConferenceDate and Time: November 19, 2020 at 9:05 a.m. ESTWebcast link: https://wsw.com/webcast/jeff141/cue/1682925A live and archived webcast of the presentation will be available in theInvestors section of the Company?s website atwww.cuebiopharma.com. .

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The companys proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate DevelopmentCue Biopharma, Inc.gzavoico@cuebio.com

Media ContactAlison ChenLifeSci Communicationsachen@lifescicomms.com